0.6375
price up icon10.87%   0.0625
after-market Dopo l'orario di chiusura: .63 -0.0075 -1.18%
loading

Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie

pulisher
07:13 AM

Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider

07:13 AM
pulisher
Apr 09, 2025

Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Novo Nordisk inks licensing pact with Lexicon for obesity candidate - MSN

Apr 09, 2025
pulisher
Apr 02, 2025

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider

Apr 02, 2025
pulisher
Apr 01, 2025

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review

Mar 31, 2025
pulisher
Mar 31, 2025

Houston-area company inks massive $1B deal for weight-loss drug - Chron

Mar 31, 2025
pulisher
Mar 31, 2025

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 31, 2025

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga

Mar 31, 2025
pulisher
Mar 29, 2025

The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

Mar 29, 2025
pulisher
Mar 29, 2025

Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize

Mar 29, 2025
pulisher
Mar 28, 2025

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily

Mar 28, 2025
pulisher
Mar 28, 2025

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Fidelity

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter

Mar 28, 2025
pulisher
Mar 28, 2025

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider

Mar 28, 2025
pulisher
Mar 28, 2025

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Mar 28, 2025
pulisher
Mar 27, 2025

Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR

Mar 27, 2025
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Capitalizzazione:     |  Volume (24 ore):